These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27989877)

  • 1. Chinese herbal medicine Fuzheng Kang-Ai decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt -mediated suppressing MUC1 expression.
    Li L; Wang S; Zheng F; Wu W; Hann SS
    J Ethnopharmacol; 2016 Dec; 194():918-929. PubMed ID: 27989877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
    Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
    J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decoction of Chinese Herbal Medicine Fuzheng Kang-Ai Induces Lung Cancer Cell Apoptosis via STAT3/Bcl-2/Caspase-3 Pathway.
    Wang S; Long S; Xiao S; Wu W; Hann SS
    Evid Based Complement Alternat Med; 2018; 2018():8567905. PubMed ID: 30046347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
    Tang Q; Xu M; Long S; Yu Y; Ma C; Wang R; Li J; Wang X; Fang F; Han L; Wu W; Wang S
    J Ethnopharmacol; 2024 Jan; 318(Pt A):116646. PubMed ID: 37269912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fuzheng Kang-Ai decoction enhances the effect of Gefitinib-induced cell apoptosis in lung cancer through mitochondrial pathway.
    Wang S; Peng Z; Li W; Long S; Xiao S; Wu W
    Cancer Cell Int; 2020; 20():185. PubMed ID: 32489321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal interaction of HOTAIR and SP1 together enhance the ability of Xiaoji decoction and gefitinib to inhibit EP4 expression.
    Wu J; Tang Q; Ren X; Zheng F; He C; Chai X; Li L; Hann SS
    J Ethnopharmacol; 2019 Jun; 237():128-140. PubMed ID: 30910577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of PI3-K/Akt and reduction of SP1 and p65 expression increase the effect of solamargine on suppressing EP4 expression in human lung cancer cells.
    Chen Y; Tang Q; Wu J; Zheng F; Yang L; Hann SS
    J Exp Clin Cancer Res; 2015 Dec; 34():154. PubMed ID: 26689593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
    Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
    J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chinese Herbal Medicine Fuzheng Kang-Ai Decoction Inhibited Lung Cancer Cell Growth through AMPKα-Mediated Induction and Interplay of IGFBP1 and FOXO3a.
    Zheng F; Wu J; Li X; Tang Q; Yang L; Yang X; Wu W; Hann SS
    Evid Based Complement Alternat Med; 2016; 2016():5060757. PubMed ID: 27057199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chinese herbal medicine Xiaoji decoction inhibited growth of lung cancer cells through AMPKα-mediated inhibition of Sp1 and DNA methyltransferase 1.
    Zhao S; Wu J; Tang Q; Zheng F; Yang L; Chen Y; Li L; Hann SS
    J Ethnopharmacol; 2016 Apr; 181():172-81. PubMed ID: 26850724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
    Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
    Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fuzheng Kang-Ai inhibits NSCLC cell proliferation via regulating hsa_circ_0048091/hsa-miR-378g/ARRDC3 pathway.
    Tang Q; Wang X; Zhou Q; Li Q; Yang X; Xu M; Wang R; Chen J; Wu W; Wang S
    Phytomedicine; 2023 Jun; 114():154819. PubMed ID: 37062135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.
    Li J; Xiang S; Zhang Q; Wu J; Tang Q; Zhou J; Yang L; Chen Z; Hann SS
    J Exp Clin Cancer Res; 2015 May; 34(1):46. PubMed ID: 25971429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crosstalk of NF-κB/P65 and LncRNA HOTAIR-Mediated Repression of MUC1 Expression Contribute to Synergistic Inhibition of Castration-Resistant Prostate Cancer by Polyphyllin 1-Enzalutamide Combination Treatment.
    Xiang S; Zou P; Wu J; Zheng F; Tang Q; Zhou J; Hann SS
    Cell Physiol Biochem; 2018; 47(2):759-773. PubMed ID: 29807357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.
    Bonaccorsi L; Marchiani S; Muratori M; Forti G; Baldi E
    J Cancer Res Clin Oncol; 2004 Oct; 130(10):604-14. PubMed ID: 15258753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
    Liu X; Carlisle DL; Swick MC; Gaither-Davis A; Grandis JR; Siegfried JM
    Exp Cell Res; 2007 Apr; 313(7):1361-72. PubMed ID: 17349623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
    Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
    Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.